Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2017-04-06 Declaration of Voting R…
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a press release dated April 6, 2017, titled 'INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL' (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of March 31, 2017. This content directly corresponds to the definition of a Declaration of Voting Results & Voting Rights Announcement, which is categorized as DVA (Declaration of Voting Results & Voting Rights Announcements). Although it mentions a future earnings release, the primary content is the monthly voting rights disclosure.
2017-04-06 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Share Issue/Capital Change Classification · 99% confidence The document is a press release ("Communiqué de presse") dated December 20, 2016, announcing the success of a capital increase ("Succès de l'augmentation de capital") where €3.03M was raised. It details the subscription results, the use of proceeds (financing R&D, new product launches, commercial development), and the resulting change in share capital structure. It also mentions an upcoming simplified merger and the next communication date (Annual Revenue 2016). The core subject is a financing activity resulting in new share issuance and capital structure change. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV).
2016-12-20 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated November 29, 2016, announcing the launch of a capital increase ('augmentation de capital') with preferential subscription rights ('droit préférentiel de souscription' or DPS). It details the terms, pricing (€2.10 per share), maximum amount (€3.39 M€), subscription period (December 6 to 14, 2016), and the legal framework for the issuance. This clearly falls under the category of financing activities and capital structure changes. The specific code for this is 'CAP' (Capital/Financing Update). Although it is a press release, the core content is the financing operation itself, not just an announcement of a report (which would be RPA or RNS). The document also mentions a potential merger, but the primary focus and detailed terms relate to the capital raise.
2016-11-29 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 95% confidence The document is a press release titled 'Chiffre d'affaires consolidé du 1er semestre 2016' (Consolidated Revenue for H1 2016). It provides key financial highlights, revenue figures, and business commentary for the first half of the year. While it contains financial data, it is an initial announcement of revenue figures rather than the full interim financial report (which is explicitly mentioned as a future publication on October 27, 2016). Therefore, it is classified as an Earnings Release (ER). H1 2016
2016-07-28 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is a press release dated July 18, 2016, announcing that Biosynex has secured a €1M loan from Bpifrance (backed by the European Investment Fund) to finance the industrial and commercial launch of innovative products, including intellectual property development and marketing. This announcement details a specific financing activity (a loan) intended to support growth and product deployment. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific financing event.
2016-07-18 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.